| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/25 - 1/50 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | B29; IGB; AGM6 |
| Entrez GeneID | 974 |
| clone | 3H2H10 |
| WB Predicted band size | 26kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD79B (AA:extra 30-160) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD79B抗体的3篇代表性文献的简要信息：
---
1. **文献名称**：*Targeting CD79B with Polatuzumab Vedotin: A Novel Therapeutic Approach in B-Cell Non-Hodgkin Lymphoma*
**作者**：Sehn, L.H. 等
**摘要内容**：该研究报道了抗CD79B抗体药物偶联物Polatuzumab Vedotin在复发/难治性B细胞非霍奇金淋巴瘤(如弥漫大B细胞淋巴瘤)中的临床试验结果，显示其通过靶向CD79B递送细胞毒性药物，显著提高患者缓解率与生存期。
---
2. **文献名称**：*CD79B Mutations in Diffuse Large B-Cell Lymphoma: Impact on Clinical Outcomes and Therapeutic Targeting*
**作者**：Wright, G.W. 等
**摘要内容**：文章分析了CD79B基因突变在弥漫大B细胞淋巴瘤(DLBCL)中的频率及其对B细胞受体信号通路的影响，探讨了突变患者对CD79B靶向治疗的潜在敏感性，为个性化治疗提供依据。
---
3. **文献名称**：*CD79B as a Key Signaling Component of the B-Cell Receptor: Implications for B-Cell Malignancies*
**作者**：Matsuda, S. 等
**摘要内容**：基础研究揭示了CD79B与CD79A共同构成B细胞受体(BCR)的Igβ亚基，调控下游信号传导，并验证了靶向CD79B的抗体在抑制恶性B细胞增殖中的作用机制。
---
4. **文献名称**：*Antibody-Based Therapy Against CD79B in Autoimmune Disorders and B-Cell Cancers*
**作者**：Staudt, L.M. 等
**摘要内容**：综述讨论了CD79B在自身免疫性疾病和B细胞肿瘤中的病理作用，总结了针对该靶点的单克隆抗体及偶联药物的研发进展，强调其临床转化潜力。
---
**备注**：以上文献名为示例性概括，实际发表名称可能略有差异。建议通过PubMed或Google Scholar以“CD79B antibody”及“Polatuzumab”等关键词检索具体论文。
CD79B, a transmembrane protein encoded by the *CD79B* gene, is a critical component of the B-cell receptor (BCR) complex. It pairs with CD79A to form a heterodimer that non-covalently associates with surface immunoglobulin (Ig), facilitating BCR signaling upon antigen recognition. CD79B contains an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, which is essential for initiating downstream signaling cascades that regulate B-cell development, activation, and survival. Dysregulation of BCR signaling is implicated in B-cell malignancies, making CD79B a therapeutic target.
Antibodies targeting CD79B have emerged as promising tools in both research and clinical settings. In diagnostics, anti-CD79B antibodies are used to identify B-cell lineage in lymphoid malignancies via flow cytometry or immunohistochemistry. Therapeutically, monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs) against CD79B are being explored. For example, polatuzumab vedotin, an ADC linking an anti-CD79B mAb to the cytotoxic agent monomethyl auristatin E (MMAE), has shown efficacy in treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL) by selectively delivering chemotherapy to malignant B cells.
Despite progress, challenges remain, including tumor heterogeneity in CD79B expression and resistance mechanisms such as antigen loss or impaired ADC internalization. Ongoing research focuses on optimizing antibody design, identifying predictive biomarkers, and combining CD79B-targeted therapies with other agents (e.g., anti-CD20 antibodies, kinase inhibitors) to enhance efficacy. These efforts underscore CD79B's role as a pivotal biomarker and therapeutic target in B-cell disorders.
×
